2VJ Stock Overview
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Ascletis Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.18 |
52 Week High | HK$0.31 |
52 Week Low | HK$0.14 |
Beta | 0.66 |
1 Month Change | -16.04% |
3 Month Change | 17.88% |
1 Year Change | -41.83% |
3 Year Change | -40.27% |
5 Year Change | -76.88% |
Change since IPO | -84.52% |
Recent News & Updates
Recent updates
Shareholder Returns
2VJ | DE Biotechs | DE Market | |
---|---|---|---|
7D | -3.3% | 0.06% | 0.07% |
1Y | -41.8% | 28.6% | 4.9% |
Return vs Industry: 2VJ underperformed the German Biotechs industry which returned 28.6% over the past year.
Return vs Market: 2VJ underperformed the German Market which returned 4.9% over the past year.
Price Volatility
2VJ volatility | |
---|---|
2VJ Average Weekly Movement | 11.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2VJ has not had significant price volatility in the past 3 months.
Volatility Over Time: 2VJ's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 243 | Jinzi Jason Wu | https://www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
2VJ fundamental statistics | |
---|---|
Market cap | €191.13m |
Earnings (TTM) | -€30.99m |
Revenue (TTM) | €7.94m |
24.1x
P/S Ratio-6.2x
P/E RatioIs 2VJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2VJ income statement (TTM) | |
---|---|
Revenue | CN¥62.38m |
Cost of Revenue | CN¥72.82m |
Gross Profit | -CN¥10.44m |
Other Expenses | CN¥232.97m |
Earnings | -CN¥243.40m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 25, 2024
Earnings per share (EPS) | -0.24 |
Gross Margin | -16.74% |
Net Profit Margin | -390.21% |
Debt/Equity Ratio | 0% |
How did 2VJ perform over the long term?
See historical performance and comparison